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Sarcoidosis is an enigmatic disease with a pathology similar to that of tuberculosis. We detected Th-1
immune responses to Mycobacterium tuberculosis ESAT-6 and KatG peptides from peripheral blood mononu-
clear cells from 15/26 sarcoidosis, 1/24 purified-protein-derivative-negative (PPD) (P< 0.0001, Fisher’s exact
test), and 7/8 PPD-positive (PPD) subjects (P  0.21). This finding provides immunologic links between
mycobacteria and systemic sarcoidosis.
While the antigen(s) responsible for eliciting the sarcoidosis
Th-1 immune response has not been identified (9, 13, 14),
reviews of sarcoidosis immunology and pathology suggest that
mycobacterial antigens could be important (6, 8). Previous
studies have reported humoral responses to mycobacterial an-
tigens among sarcoidosis subjects (4, 15) as well as the detec-
tion of mycobacterial nucleic acids and proteins in sarcoidosis
granulomas (3, 5, 15). We performed enzyme-linked immuno-
spot (ELISPOT) assays to assess for cellular recognition of two
Mycobacterium sp. antigens (ESAT-6, an immunodominant T-
cell antigen present in some members of the Mycobacterium
tuberculosis complex but absent in Mycobacterium bovis BCG
[2], and KatG, a catalase-peroxidase [7]) from peripheral blood
mononuclear cells (PBMC) from 26 sarcoidosis, 24 purified-
protein-derivative-negative (PPD), and 11 PPD-positive (PPD)
subjects.
This study was approved by the Vanderbilt University Insti-
tutional Review Board for human studies, and informed writ-
ten consent was obtained from the study participants or their
surrogates. All sarcoidosis subjects from the available pa-
tient database of the Vanderbilt University Pulmonary
Clinic were invited to participate in the study. For inclusion
in this study, the clinical, histological, and microbiologic
criteria used to define sarcoidosis were as previously de-
scribed (3). Healthy PPD volunteers were required to have
undergone PPD testing by the Vanderbilt employee health
services. PPD-positive subjects had written documentation
of their PPD statuses and had no evidence of active disease
at the time of study enrollment.
The amino acid sequences for the 17 ESAT-6 peptides,
15-mers overlapping by 10 amino acids, were as previously
described (11). KatG peptides, 15-mers overlapping by 10
amino acids, were derived from the amino acid sequence of M.
tuberculosis (GenBank accession number NP 216424) and are
listed in Table 1. Each ESAT-6 and KatG peptide was synthe-
sized by solid-phase 9-fluorenylmethoxy carbonyl (Fmoc)
chemistry (Genemed Synthesis, San Diego, CA), to a purity of
70%. Identity was confirmed by mass spectroscopy and purity
by high-performance liquid chromatography. PBMC were iso-
lated from blood samples drawn into tubes containing EDTA,
separated by Ficoll-Hypaque density gradient separation (Am-
ersham Biosciences), cryopreserved in fetal calf serum with
10% dimethyl sulfoxide, and stored in liquid nitrogen until the
time of the analysis.
ELISPOT assays were performed as previously described
(1). The number of specific gamma interferon-secreting T cells
was calculated by subtracting the mean negative-control value
from the mean spot-forming-cell (SFC) count for duplicate
wells inoculated with peptide. Negative controls always had
50 SFC per 106 input cells. A positive response was defined
as a concentration of at least 50 SFC/106 PBMC that is at least
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TABLE 1. Amino acid sequences for M. tuberculosis
KatG peptidesa
Codons Peptide sequence
91–105 ...........................................................WPADYGHYGPLFIRM
95–110 ...........................................................GHYGPLFIRMAWHAA
101–115 .........................................................LFIRMAWHAAGTYRI
106–120 .........................................................AWHAAGTYRIHDGRG
111–125 .........................................................GTYRIHDGRGGAGGG
116–130 .........................................................HDGRGGAGGGMQRFA
121–135 .........................................................GAGGGMQRFAPLNSW
126–140 .........................................................MQRFAPLNSWPDNAS
301–315 .........................................................KSSYGTGTGKDAITS
306–320 .........................................................TGTGKDAITSGIEVV
311–525 .........................................................DAITSGIEVVWTNTP
316–330 .........................................................GIEVVWTNTPTKWDN
321–335 .........................................................WTNTPTKWDNSFLEI
326–340 .........................................................TKWDNSFLEILYGYE
331–345 .........................................................SFLEILYGYEWELTK
a GenBank accession number NP 216424.
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TABLE 2. Clinical and demographic characterization of study participantsa
Subject Age, race, and sex Disease site(s) Immunosuppressiongroup(s)
No. of cellsb for indicated
protein
KatG ESAT-6
Sarcoidosis 1 58, AA, F C, P Steroids 580 100
Sarcoidosis 2 53, AA, M P Pentoxifylline 480 320
Sarcoidosis 3 50, C, M P None 300 550
Sarcoidosis 4 55, C, F P Steroids 300 280
Sarcoidosis 5 52, AA, F P None 110 500
Sarcoidosis 6 50, AA, M P None 90 130
Sarcoidosis 7 58, AA, M P Steroids 510 50
Sarcoidosis 8 52, AA, F P Steroids, pentoxifylline 500 50
Sarcoidosis 9 40, C, M P None 50 590
Sarcoidosis 10 33, C, F P None 420 50
Sarcoidosis 11 51, C, F P Steroids 370 50
Sarcoidosis 12 31, AA, M C, P, CNS Steroids 240 50
Sarcoidosis 13 33, C, F P None 50 100
Sarcoidosis 14 46, AA, M P HIV 120 50
Sarcoidosis 15 62, C, M P None 110 50
Sarcoidosis 16 47, C, F P, CNS Steroids 50 50
Sarcoidosis 17 51, AA, F C Steroids 50 50
Sarcoidosis 18 42, AA, F P Steroids 50 50
Sarcoidosis 19 49, AA, F C, P Steroids 50 50
Sarcoidosis 20 22, C, M P Steroids 50 50
Sarcoidosis 21 41, C, F C, P None 50 50
Sarcoidosis 22 47, AA, M P None 50 50
Sarcoidosis 23 47, C, F P Steroids 50 50
Sarcoidosis 24 51, C, F P None 50 50
Sarcoidosis 25 37, C, M P None 50 50
Sarcoidosis 26 61, C, F P Pentoxifylline 50 50
Control 1 36, AA, F None None 50 380
Control 2 37, C, M None None 50 50
Control 3 23, C, M None None 50 50
Control 4 58, C, F None None 50 50
Control 5 25, C, F None None 50 50
Control 6 30, C, M None None 50 50
Control 7 27, AA, M None None 50 50
Control 8 33, C, F None None 50 50
Control 9 31, C, M None None 50 50
Control 10 31, C, F None None 50 50
Control 11 25, H, M None None 50 50
Control 12 32, C, M None None 50 50
Control 13 24, C, F None None 50 50
Control 14 37, C, F None None 50 50
Control 15 27, AA, F None None 50 50
Control 16 33, AA, F None None 50 50
Control 17 33, C, F None None 50 50
Control 18 31, AA, M None None 50 50
Control 19 51, C, F None None 50 50
Control 20 35, C, F None None 50 50
Control 21 34, AA, F None None 50 50
Control 22 34, C, M None None 50 50
Control 23 37, AA, F None None 50 50
Control 24 32, AA, F None None 50 50
PPD 1 45, C, F None None 400 500
PPD 2 41, AA, F None None 750 230
PPD 3 34, C, F None None 430 400
PPD 4 57, AA, M None None 60 500
PPD 5 49, C, F None None 280 50
PPD 6 63, C, F None None 180 50
PPD 7 64, C, F None None 80 50
PPD 8 49, C, F None None 50 50
BCG 1 41, A, M None None 50 50
BCG 2 33, I, M None None 50 50
BCG 3 42, I, F None None 50 50
a Ages are in years. AA, African American; A, African; C, Caucasian; H, Hispanic; I, Asian Indian; F, female; M, male; C, cutaneous; P, pulmonary; CNS, central
nervous system; HIV, human immunodeficiency virus.
b Number of gamma interferon-producing spot-forming cells per million PBMC.
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three times higher than the background level. The research
assistants were blind to the clinical diagnoses of the study
participants throughout the analysis. Comparisons of distribu-
tions of T-cell frequencies were performed using the Kruskal-
Wallis test. Categorical comparisons were analyzed using Fish-
er’s exact test. All P values are two sided and were determined
using R (version 2.1.1).
Sixty-one subjects were recruited for participation in the
study. Of the 26 sarcoidosis subjects, 46% were African Amer-
ican, 42% were male, and 58% were 50 years of age or
younger. Of the 24 PPD patients, 33% were African Amer-
ican, 4% were Hispanic, 38% were male, and 88% were 50
years of age or younger (Table 2). Of the 11 PPD subjects (8
subjects with latent tuberculosis and 3 BCG vaccinees), 18%
were African American, 9% Haitian, 18% Asian Indian, 27%
male, and 72% 50 years of age or younger (Table 2).
Among the 15 KatG peptides used in the ELISPOT assay, 13
of the 26 sarcoidosis subjects recognized KatG peptide 13
(codons 321 to 335) (Table 2). None of the 24 PPD or the 3
BCG-vaccinated subjects recognized any of the 15 peptides
(Table 2). Seven of the eight subjects with latent tuberculosis
infection (Table 2, PPD 1 to 8) recognized KatG peptides 13
and 14 (codons 326 to 340). The immune recognition of KatG
peptide 13 by 13 of 26 sarcoidosis subjects compared to that by
0 of 24 PPD control subjects was statistically significant (P 
0.0001) (Table 2). There was no significant difference be-
tween the results for sarcoidosis subjects and subjects with
latent tuberculosis. We also compared the frequencies of
KatG peptide 13-specific T cells in each group. Consistent
with the above-described analysis, the T-cell frequencies for
sarcoidosis subjects were higher than those for PPD sub-
jects (P  0.0001) and lower than those for PPD subjects,
though the latter difference was not statistically significant
(P  0.17) (Fig. 1).
Of the 17 ESAT-6 peptides tested, there was recognition of
ESAT-6 peptide 14 (NNALQNLARTISEAG) only. Eight of
26 sarcoidosis subjects, 1 of 24 control subjects (P  0.024),
and 4 of 8 PPD subjects (P  0.41) (Table 2) recognized
ESAT-6 peptide 14. While two of the sarcoidosis subjects rec-
ognized ESAT-6 peptide 14 only (Table 2, sarcoidosis 9 and
13), six sarcoidosis subjects displayed immune recognition of
both ESAT-6 peptide 14 and KatG peptide 13 (Table 2, sar-
coidosis 1 to 6). Only one control subject recognized ESAT-6
peptide 14 (Table 2, control 1); the magnitude of this response
was similar to that observed in the sarcoidosis and PPD
participants (Fig. 2). The four PPD subjects who recognized
ESAT-6 peptide 14 also recognized KatG peptide 13 (Table 2,
PPD 1 to 4). There was no significant difference in the T-cell
frequencies for ESAT-6 peptide 14 between the sarcoidosis
and PPD subjects (P 0.27) (Fig. 2). The three subjects with
BCG vaccination recognized none of the KatG or ESAT-6
peptides. All study participants exhibited strong responses to
phytohemagglutinin. Overall, 15 of 26 (58%) sarcoidosis sub-
jects recognized KatG peptide 13 or ESAT-6 peptide 14, com-
pared to 1 of 24 (4%) PPD subjects (P  0.0001) and 7 of 8
PPD subjects (P  0.21).
This study suggests for the first time that despite the nega-
tive culture and histology of sarcoidosis specimens, mycobac-
FIG. 1. Distribution of T-cell frequencies for PPD control,
PPD, and sarcoidosis subjects for KatG peptide 13. The bars repre-
sent the 25th percentile, median (50th percentile), and 75th percentile
for each group; for PPD controls, these three quantities are all equal
to zero. The PPD group included the greatest percentage of study
participants recognizing KatG peptide 13 as well as the highest median
T-cell frequency. Although the sarcoidosis subjects are PPD and
have no culture evidence of infection by mycobacteria, the distribution
of the T-cell frequencies for the sarcoidosis subjects was significantly
different from that for the PPD controls (P  0.0001) and was closer
to that for the PPD subjects (P  0.17).
FIG. 2. Distribution of T-cell frequencies for the PPD control,
PPD, and sarcoidosis subjects for ESAT-6 peptide 14. The bars
represent the 25th percentile, median (50th percentile), and 75th per-
centile for each group; for PPD controls, these three quantities are
all equal to zero; for sarcoidosis subjects, the 25th percentiles and
medians are both equal to zero. Although all of the sarcoidosis subjects
tested were PPD, there was a significant difference in the distribution
of the T-cell frequencies for the sarcoidosis and PPD subjects (P 
0.024). The lone PPD subject who recognized ESAT-6 peptide 14
had a T-cell frequency comparable to those for the sarcoidosis and
PPD subjects. Comparison of the sarcoidosis and PPD subjects
revealed that there was no significant difference in the distributions of
the T-cell frequencies for ESAT-6 peptide 14 (P  0.27).
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terial antigens induce T-cell-specific responses in the blood of
sarcoidosis patients at frequencies and magnitudes of response
comparable to those for patients who are PPD. The T-cell
frequencies observed in this study are consistent with prior
reports of immune recognition of mycobacterial antigens by
tuberculosis subjects (Table 2) (10–12). The observation of a
cellular immune response to Mycobacterium KatG antigens in
57% of sarcoidosis subjects closely parallels the results for
prior PCR analysis (3) as well as the degree of an adaptive
immune response to M. tuberculosis KatG proteins among sar-
coidosis subjects previously reported in an independent study
(15). We did not assess for immune reactivity to the entire
KatG protein sequence, so it is possible that other immuno-
genic peptides exist. The detection of immune recognition of
ESAT-6 peptide 14 and KatG peptide 13 is unlikely to be
secondary to that of nonspecific reactivity or exposure to rou-
tine environmental mycobacteria. First, no significant reactivity
was observed among the PPD control subjects, who live in
the same region as the sarcoidosis and PPD subjects. Second,
ESAT-6 peptide 14 contains the amino acid sequence NNAL
QNLARTISEAG, which has been previously reported to in-
duce a CD8 T-cell response from tuberculosis patients (10).
The absence of immune reactivity to ESAT-6 peptides by
BCG-vaccinated subjects served as a good internal control for
the specificity of the ELISPOT assay. M. bovis BCG does not
contain esat-6 in its genome; thus, one would not expect to see
immune reactivity to 15 ESAT-6 proteins among persons who
had undergone BCG vaccination. These results support the
hypothesis that mycobacterial antigens may have a role in
sarcoidosis pathogenesis by demonstrating that they induce
T-cell-antigen-specific Th-1 responses that are known to be
important in sarcoidosis granuloma formation. This associa-
tion does not imply causality but does provide another link
between sarcoidosis and mycobacteria, supporting further in-
vestigation of the role of mycobacteria in sarcoidosis immuno-
pathogenesis.
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